Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.63 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946002 | 0.85 | CNR2 (0.65) | CNR2TAS2R14KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL5725967 | 0.81 | ALDH1A1 (0.49) | CNR2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5046426 | 0.80 | CNR2 (0.61) | CNR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL5048052 | 0.78 | CNR2 (0.75) | CNR2TAS2R14 | |
| SCHEMBL5050520 | 0.76 | TAS2R14 (0.56) | CNR2TAS2R14ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5050411 | 0.75 | TAS2R14 (0.58) | CNR2TAS2R14KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL5049446 | 0.75 | CNR2 (0.57) | CNR2ALDH1A1 | |
| SCHEMBL4948807 | 0.75 | PTGER2 (0.56) | CNR2 | |
| SCHEMBL5047940 | 0.74 | MAPT (0.64) | CNR2TAS2R14 | |
| SCHEMBL15677741 | 0.74 | RXFP1 (0.63) | CNR2TAS2R14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1599605-A | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PFIZER PROD INC (US) | 2005-03-23 | — | — | CN | claimed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | claimed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| CN-1599605-A | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PFIZER PROD INC (US) | 2005-03-23 | — | — | CN | disclosed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | disclosed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | CAMERON KIMBERLY O (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1121939-A2 | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | Pfizer Products Inc. (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056060-A1 | Treatment of osteoporsis with EP2/EP4 receptor selective agonists | PTGER2, PTGER1, PTGER4 | CNR2 71/4885TAS2R14 1752/4885KEAP1 1663/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | CNR2 23/4885TAS2R14 2271/4885KEAP1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.